Abstract
The purpose of this study was to evaluate inherited and acquired prothrombotic risk factors among children with malignancies who have thrombosis and emphasize the importance of inherited prothrombotic risk factors. Thirty-seven consecutive children with thrombosis and malignancy were included in this study. The patients were evaluated separately for time of development of thrombosis, insertion of a central venous line (CVL), history of l-asparaginase usage, and recent infections. Prothrombotic risk factors such as factor V G1691A and prothrombin G20210A mutation, protein C, protein S, antithrombin III deficiencies, factor VIII and lipoprotein(a) elevation, and antiphospholipid antibodies were analyzed for all patients. Of 387 children with thrombosis, 37 (9.5%) had a malignancy. Thrombosis was detected in 9 patients at the time of diagnosis, during maintenance therapy in 25 patients, and after the discontinuation of treatment in 3 patients. One or two additional prothrombotic risk factors other than l-asparaginase therapy and insertion of central venous lines were present in 20 of these patients (54%). It was found that eight patients had the factor V G1691A mutation in the heterozygote state. One of them had the factor V G1691A mutation associated with a history of infection and one patient had the factor V G1691A mutation associated with factor VIII elevation. One had the the prothrombin G20210A mutation in the heterozygote state, four had lipoprotein(a) elevation, two had factor VIII elevation, one had a decreased protein S level, one had a decreased protein C level, one had antiphospholipid positivity, and two had histories of infection. Malignancy is an important risk factor for the development of childhood thrombosis. However, the risk of thrombosis increases when accompanied by additional prothrombotic risk factors. For this reason, especially children with malignancy and at high risk for the development of thrombosis, such as those who have received l-asparaginase or a replaced CVL during their therapy, might be screened for additional prothrombotic risk factors and appropriate measures might be taken to prevent the development of thrombosis.
Similar content being viewed by others
References
Sutherland DE, Weitz IC, Liebman HA (2003) Thromboembolic complications of cancer epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72:43–52
Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 17:117–121
Rodger LB (2003) Thrombosis and thrombophilia: diagnosis and management. Hematol Oncol Clin North Am 17:9–37
Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173–181
Gouın I, Samama M (1999) Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 25:167–172
Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109–111
Bell RW (1996) The fibrinolytic system in neoplasia. Semin Thromb Hemost 22:459–478
Guarini A, Mussoni A, Gugliatta L, Chetti L, Niewiarowski T, Catani L, Macchi S, Donati MB, Tura S (1987) Depressed fibrinolysis in patients with acute leukemia. Br J Haematol 66:327–330
Goldschmidt B, Koos R (1984) Metabolism of fibrinogen in children with acute lymphoblastic leukemia. Eur J Pediatr 143:140–144
Semeraro N, Montemurro P, Giardona P, Schettini F, Santoro N, Mattia D, Giordano D, Ronese M, Colucci M (1990) Unbalanced coagulation fibrinolysis potential during l-asparaginase therapy in children with acute lymphoblastic leukemia. Thromb Haemost 64:38–40
Nowak-Göttl U, Heineche A, Von Kries R, Nürnberger W, Münchow N, Junker R (2001) Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 103:165–172
Wilimas JA, Hudson M, Rao B, Luo X, Lott L, Kaste SC (1998) Late vascular occlusion of central lines in pediatric malignancies. Pediatrics 101:1–5
Bona DR (1999) Thrombotic complication of central venous catheters in cancer patients. Semin Thromb Hemost 25:147–155
Ehrenforth S, Junker R, Koch HG, Kreuz W, Münchow N, Scharrer I, Nowak-Göttl U (1999) Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 158:97–104
Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack, Schwabe D, Ehrenforth S (1999) Prospective evaluation of the thrombotic risk in children with acute leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93:1595–1599
Nowak-Göttl U, Dübbers A, Kececioglu D, Koch GH, Kotthoff S, Runde J, Vielhaber H (1997) Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 131:608–612
Wermes C, Prondzinski D, Lichtinghagen R, Barthels M, Welte K, Sykora KW (1999) Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158:143–146
Knofler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, Müller D, Rupprecht E, Kabus M (1999) Clinical importance of prothrombotic risk factors in pediatric patients with malignancy—impact of central venous lines. Eur J Pediatr 158 [Suppl 3]:S147–S150
Sifontes MT, Nuss R, Hunger SP, Williams J, Jacobson LS, Manco-Johnson MJ (1997) The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96:484–498
Gurgey A, Buyukpamukcu M, Baykurt C, Yalcın B, Gogus S (1997) Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma. Med Pediatr Oncol 56:189–190
Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67
Poort SR, Rosendaal FR, Reistma PH, Bertina RM (1996) A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850
Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691 G–A) mutation in Turkey. Turk J Pediatr 39:313–315
Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D et al (1994) Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood 83:1251–1257
Nowak-Göttl U, Junker R, Hartmaier H, Koch HG, Münchow N, Assmann G, Von Eckardstein A (1999) Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 100:743–748
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ünal, S., Varan, A., Yalçın, B. et al. Evaluation of thrombotic children with malignancy. Ann Hematol 84, 395–399 (2005). https://doi.org/10.1007/s00277-005-1004-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-1004-x